Home›Trial›NCT05504837
🔬NCT05504837Phase 1RECRUITING

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Study Summary

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Conditions
Cystic Fibrosis
Interventions / Drugs
KB407 (Nebulization)
View on ClinicalTrials.gov ↗
Sponsor
KRYS
Krystal Biotech
Gene Therapy
F30/100
Study Details
Enrollment12 participants
Primary Completion—
Lead SponsorKrystal Biotech, Inc.
Data Retrieved2026-04-11 04:19:09.549435+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.